Lilly culls most of its clinical immuno-oncology pipeline

Eli Lilly disclosed the pharma has discontinued development of four immuno-oncology programs on Thursday -- including one that cost $1.6 billion to acquire -- as part of its 4Q19 earnings update.

The moves leave Eli Lilly and Co. (NYSE:LLY) with only two disclosed internal candidates in the clinic that clearly fall within the immuno-oncology space...